These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38425116)

  • 1. Improving Type 2 Diabetes Care with Extended-Release Metformin: Real-Life Insights from a Physician Educational Program.
    Molteni L; Marelli G; Castagna G; Brambilla L; Acerbis M; Alberghina F; Carpani A; Chiavenna E; Ferlini MG; Impellizzeri C; Paredi R; Rigamonti A; Rivolta G; Disoteo OE
    Endocr Metab Immune Disord Drug Targets; 2024; 24(12):1422-1430. PubMed ID: 38425116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
    Derosa G; D'Angelo A; Romano D; Maffioli P
    Drug Des Devel Ther; 2017; 11():1481-1488. PubMed ID: 28553078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.
    Fujioka K; Pans M; Joyal S
    Clin Ther; 2003 Feb; 25(2):515-29. PubMed ID: 12749511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes.
    Aggarwal N; Singla A; Mathieu C; Montanya E; Pfeiffer AFH; Johnsson E; Zhao J; Iqbal N; Bailey C
    Diabetes Obes Metab; 2018 Feb; 20(2):463-467. PubMed ID: 28857388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
    Hermans M; Van Gaal L; Rézette I; Daci E; MacDonald K; Denhaerynck K; Vancayzeele S; De Meester L; Clemens A; Yee B; Abraham I
    Prim Care Diabetes; 2016 Dec; 10(6):425-433. PubMed ID: 27388795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus.
    Derosa G; Romano D; Bianchi L; D'Angelo A; Maffioli P
    J Clin Pharmacol; 2015 Apr; 55(4):409-14. PubMed ID: 25328091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes.
    Kim JD; Park CY; Cha BY; Ahn KJ; Kim IJ; Park KS; Lee HW; Min KW; Won JC; Chung MY; Kim JT; Kang JG; Park SW
    Clin Ther; 2018 May; 40(5):752-761.e2. PubMed ID: 29729957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.
    Henry RR; Frias JP; Walsh B; Skare S; Hemming J; Burns C; Bicsak TA; Baron A; Fineman M
    PLoS One; 2018; 13(9):e0203946. PubMed ID: 30252913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of extended-release metformin in treatment of type 2 diabetes mellitus].
    Zhang JP; Yang WY; Hong TP; Yang JK; Xiao WH; Gao HW; Yang Y
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(18):1238-40. PubMed ID: 17686255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study.
    Donnelly LA; Morris AD; Pearson ER
    Diabetes Obes Metab; 2009 Apr; 11(4):338-42. PubMed ID: 19267712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus.
    Bhansali A; Masoodi SR
    J Assoc Physicians India; 2005 May; 53():441-5. PubMed ID: 16124352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes.
    Schwartz S; Fonseca V; Berner B; Cramer M; Chiang YK; Lewin A
    Diabetes Care; 2006 Apr; 29(4):759-64. PubMed ID: 16567811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.
    Duckworth W; Marcelli M; Padden M; Kellick K; Duhancik T; Wilhardt M; Colgan K; Romie A
    J Manag Care Pharm; 2003; 9(3):256-62. PubMed ID: 14613469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies.
    Fujioka K; Brazg RL; Raz I; Bruce S; Joyal S; Swanink R; Pans M
    Diabetes Obes Metab; 2005 Jan; 7(1):28-39. PubMed ID: 15642073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.
    Alvarez Guisasola F; Tofé Povedano S; Krishnarajah G; Lyu R; Mavros P; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():25-32. PubMed ID: 18435671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
    Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
    Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
    Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.